Neurological complications in chronic kidney disease patients

Nephrology Dialysis Transplantation

Volumn 31, Issue 10, 2016, Pages 1606-1614

  Chillon, Jean Marc ^a,b   Massy, Ziad A ^c,d,e   Stengel, Bénédicte ^d,e  

^a UNIVERSITÉ DE PICARDIE JULES VERNE   (France)

^b AMIENS UNIVERSITY HOSPITAL   (France)

^c HÔPITAL AMBROISE PARÉ   (France)

^d CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

^e LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

Author keywords

cerebrovascular disease; chronic kidney disease; cognitive impairment; end stage renal disease; epidemiology

Indexed keywords

AMLODIPINE; ANTIANEMIC AGENT; ANTILIPEMIC AGENT; INDAPAMIDE; INTERCELLULAR ADHESION MOLECULE 1; LISINOPRIL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OLMESARTAN; PERINDOPRIL; UREMIC TOXIN; VASCULAR CELL ADHESION MOLECULE 1;

ANEMIA; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; BLOOD VESSEL CALCIFICATION; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CHRONIC INFLAMMATION; CHRONIC KIDNEY DISEASE; COGNITIVE DEFECT; DISEASE ASSOCIATION; DISEASE SEVERITY; ENDOTHELIAL DYSFUNCTION; HUMAN; INCIDENCE; NEUROLOGICAL COMPLICATION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; UREMIA; ANIMAL; CEREBROVASCULAR DISORDERS; COMPLICATION; NEUROCOGNITIVE DISORDERS; PATHOLOGY; RENAL INSUFFICIENCY, CHRONIC; RISK FACTOR;

ANIMALS; CEREBROVASCULAR DISORDERS; HUMANS; NEUROCOGNITIVE DISORDERS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS;

EID: 84994868531     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfv315     Document Type: Review

References (85)

1. Seliger SL, Gillen DL, Longstreth WT, Jr, et al. Elevated risk of stroke among patients with end-stage renal disease. Kidney Int 2003; 64: 603-609
2. Murray AM. Cognitive impairment in the aging dialysis and chronic kidney disease populations: an occult burden. Adv Chronic Kidney Dis 2008; 15: 123-132
3. Seliger SL, Siscovick DS, Stehman-Breen CO, et al. Moderate renal impairment and risk of dementia among older adults: the Cardiovascular Health Cognition Study. J Am Soc Nephrol 2004; 15: 1904-1911
4. Iseki K, Fukiyama K. Clinical demographics and long-Term prognosis after stroke in patients on chronic haemodialysis. The Okinawa Dialysis Study (OKIDS) Group. Nephrol Dial Transplant 2000; 15: 1808-1813
5. Nakatani T, Naganuma T, Uchida J, et al. Silent cerebral infarction in hemodialysis patients. Am J Nephrol 2003; 23: 86-90
6. Lass P, Buscombe JR, Harber M, et al. Cognitive impairment in patients with renal failure is associated with multiple-infarct dementia. Clin Nucl Med 1999; 24: 561-565
7. Kuo CC, Lee CT, Ho SC, et al. Haemodialysis and the risk of stroke: a population-based cohort study in Taiwan, a country of high incidence of end-stage renal disease. Nephrology (Carlton) 2012; 17: 243-248
8. Wang HH, Hung SY, Sung JM, et al. Risk of stroke in long-Term dialysis patients compared with the general population. Am J Kidney Dis 2014; 63: 604-611
9. Bos MJ, Koudstaal PJ, Hofman A, et al. Decreased glomerular filtration rate is a risk factor for hemorrhagic but not for ischemic stroke: the Rotterdam Study. Stroke 2007; 38: 3127-3132
10. Holzmann MJ, Aastveit A, Hammar N, et al. Renal dysfunction increases the risk of ischemic and hemorrhagic stroke in the general population. Ann Med 2012; 44: 607-615
11. Mahmoodi BK, Yatsuya H, Matsushita K, et al. Association of kidney disease measures with ischemic versus hemorrhagic strokes: pooled analyses of 4 prospective community-based cohorts. Stroke 2014; 45: 1925-1931
12. Li Z, Wang A, Cai J, et al. Impact of proteinuria and glomerular filtration rate on risk of ischaemic and intracerebral hemorrhagic stroke: a result from the Kailuan study. Eur J Neurol 2015; 22: 355-360
13. Power A, Chan K, Singh SK, et al. Appraising stroke risk in maintenance hemodialysis patients: a large single-center cohort study. Am J Kidney Dis 2012; 59: 249-257
14. Kim CD, Lee HJ, Kim DJ, et al. High prevalence of leukoaraiosis in cerebral magnetic resonance images of patients on peritoneal dialysis. Am J Kidney Dis 2007; 50: 98-107
15. Shimoyama T, Kimura K, Shibazaki K, et al. Maintenance hemodialysis independently increases the risk of early death after acute intracerebral hemorrhage. Cerebrovasc Dis 2013; 36: 47-54
16. Masson P, Kelly PJ, Craig JC, et al. Risk of stroke in patients with ESRD. Clin J Am Soc Nephrol 2015 Jul 24 (epub ahead of print).
17. Fazekas G, Fazekas F, Schmidt R, et al. Brain MRI findings and cognitive impairment in patients undergoing chronic hemodialysis treatment. J Neurol Sci 1995; 134: 83-88
18. Naganuma T, Takemoto Y, Shoji T, et al. Factors associated with cerebral white matter hyperintensities in haemodialysis patients. Nephrology (Carlton) 2012; 17: 561-568
19. Watanabe A. Cerebral microbleeds and intracerebral hemorrhages in patients on maintenance hemodialysis. J Stroke Cerebrovasc Dis 2007; 16: 30-33
20. Yokoyama S, Hirano H, Uomizu K, et al. High incidence of microbleeds in hemodialysis patients detected by T2-weighted gradient-echo magnetic resonance imaging. Neurol Med Chir (Tokyo) 2005; 45: 556-560
21. Naganuma T, Takemoto Y, Yamasaki T, et al. Factors associated with silent cerebralmicrobleeds in hemodialysis patients. Clin Nephrol 2011; 75: 346-355
22. Murray AM, Seliger S, Lakshminarayan K, et al. Incidence of stroke before and after dialysis initiation in older patients. J Am Soc Nephrol 2013; 24: 1166-1173
23. Madero M, Sarnak MJ. Does hemodialysis hurt the brain? Semin Dial 2011; 24: 266-268
24. Toyoda K, Fujii K, Ando T, et al. Incidence, etiology, and outcome of stroke in patients on continuous ambulatory peritoneal dialysis. Cerebrovasc Dis 2004; 17: 98-105
25. Hojs Fabjan T, Hojs R. Stroke and renal dysfunction. Eur J Intern Med 2014; 25: 18-24
26. Koren-Morag N, Goldbourt U, Tanne D. Renal dysfunction and risk of ischemic stroke or TIA in patients with cardiovascular disease. Neurology 2006; 67: 224-228
27. Tsukamoto Y, Takahashi W, Takizawa S, et al. Chronic kidney disease in patients with ischemic stroke. J Stroke Cerebrovasc Dis 2012; 21: 547-550
28. Lee M, Saver JL, Chang KH, et al. Low glomerular filtration rate and risk of stroke: meta-Analysis. BMJ 2010; 341: c4249
29. Lee M, Saver JL, Chang KH, et al. Impact of microalbuminuria on incident stroke: a meta-Analysis. Stroke 2010; 41: 2625-2631
30. Lee M, Saver JL, Chang KH, et al. Level of albuminuria and risk of stroke: systematic review and meta-Analysis. Cerebrovasc Dis 2010; 30: 464-469
31. Ninomiya T, Perkovic V, Verdon C, et al. Proteinuria and stroke: a meta-Analysis of cohort studies. Am J Kidney Dis 2009; 53: 417-425
32. Masson P, Webster AC, Hong M, et al. Chronic kidney disease and the risk of stroke: a systematic review and meta-Analysis. Nephrol Dial Transplant 2015; 30: 1162-1169
33. Ovbiagele B. Chronic kidney disease and risk of death during hospitalization for stroke. J Neurol Sci 2011; 301: 46-50
34. Lima HN, Cabral NL, Franklin J, et al. Age dependent impact of estimated glomerular filtration rate on long-Term survival after ischaemic stroke. Nephrology (Carlton) 2012; 17: 725-732
35. Kuriyama N, Mizuno T, Ohshima Y, et al. Intracranial deep white matter lesions (DWLs) are associated with chronic kidney disease (CKD) and cognitive impairment: a 5-year follow-up magnetic resonance imaging (MRI) study. Arch Gerontol Geriatr 2013; 56: 55-60
36. Shima H, Ishimura E, Naganuma T, et al. Decreased kidney function is a significant factor associated with silent cerebral infarction and periventricular hyperintensities. Kidney Blood Press Res 2011; 34: 430-438
37. Takahashi W, Tsukamoto Y, Takizawa S, et al. Relationship between chronic kidney disease and white matter hyperintensities on magnetic resonance imaging. J Stroke Cerebrovasc Dis 2012; 21: 18-23
38. Vogels SC, Emmelot-Vonk MH, Verhaar HJ, et al. The association of chronic kidney disease with brain lesions on MRI or CT: a systematic review. Maturitas 2012; 71: 331-336
39. Ovbiagele B, Wing JJ, Menon RS, et al. Association of chronic kidney disease with cerebral microbleeds in patients with primary intracerebral hemorrhage. Stroke 2013; 44: 2409-2413
40. Ryu WS, Lee SH, Kim CK, et al. The relation between chronic kidney disease and cerebral microbleeds: difference between patients with and without diabetes. Int J Stroke 2012; 7: 551-557
41. Umemura T, Kawamura T, Sakakibara T, et al. Microalbuminuria is independently associated with deep or infratentorial brain microbleeds in hypertensive adults. Am J Hypertens 2012; 25: 430-436
42. Conde SA, Fernandes N, Santos FR, et al. Cognitive decline, depression and quality of life in patients at different stages of chronic kidney disease. J Bras Nefrol 2010; 32: 242-248
43. Bugnicourt JM, Godefroy O, Chillon JM, et al. Cognitive disorders and dementia in CKD: the neglected kidney-brain axis. J Am Soc Nephrol 2013; 24: 353-363
44. Kalirao P, Pederson S, Foley RN, et al. Cognitive impairment in peritoneal dialysis patients. Am J Kidney Dis 2011; 57: 612-620
45. Helmer C, Stengel B, Metzger M, et al. Chronic kidney disease, cognitive decline, and incident dementia: the 3C Study. Neurology 2011; 77: 2043-2051
46. Madero M, Gul A, Sarnak MJ. Cognitive function in chronic kidney disease. Semin Dial 2008; 21: 29-37
47. Betriu A, Martinez-Alonso M, Arcidiacono MV, et al. Prevalence of subclinical atheromatosis and associated risk factors in chronic kidney disease: the NEFRONA study. Nephrol Dial Transplant 2014; 29: 1415-1422
48. Chen YC, Su YC, Lee CC, et al. Chronic kidney disease itself is a causal risk factor for stroke beyond traditional cardiovascular risk factors: a nationwide cohort study in Taiwan. PLoS One 2012; 7: e36332
49. Watanabe K, Watanabe T, Nakayama M. Cerebro-renal interactions: impact of uremic toxins on cognitive function. Neurotoxicology 2014; 44: 184-193
50. De Deyn PP, Vanholder R, Eloot S, et al. Guanidino compounds as uremic (neuro)toxins. Semin Dial 2009; 22: 340-345
51. D'Hooge R, Van de Vijver G, Van Bogaert PP, et al. Involvement of voltageand ligand-gated Ca2+ channels in the neuroexcitatory and synergistic effects of putative uremic neurotoxins. Kidney Int 2003; 63: 1764-1775
52. De Deyn PP, Vanholder R, D'Hooge R. Nitric oxide in uremia: effects of several potentially toxic guanidino compounds. Kidney Int Suppl 2003; 63: S25-S28
53. Bugnicourt JM, Da Silveira C, Bengrine A, et al. Chronic renal failure alters endothelial function in cerebral circulation in mice. Am J Physiol Heart Circ Physiol 2011; 301: H1143-H1152
54. Kielstein JT, Donnerstag F, Gasper S et al.ADMAincreases arterial stiffness and decreases cerebral blood flow in humans. Stroke 2006; 37: 2024-2029
55. Khan U, Hassan A, Vallance P, et al. Asymmetric dimethylarginine in cerebral small vessel disease. Stroke 2007; 38: 411-413
56. Watanabe H, Miyamoto Y, Otagiri M, et al. Update on the pharmacokinetics and redox properties of protein-bound uremic toxins. J Pharm Sci 2011; 100: 3682-3695
57. Six I, Maizel J, Barreto FC, et al. Effects of phosphate on vascular function under normal conditions and influence of the uraemic state. Cardiovasc Res 2012; 96: 130-139
58. Jono S, McKee MD, Murry CE, et al. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 2000; 87: E10-E17
59. Muteliefu G, Enomoto A, Jiang P, et al. Indoxyl sulphate induces oxidative stress and the expression of osteoblast-specific proteins in vascular smooth muscle cells. Nephrol Dial Transplant 2009; 24: 2051-2058
60. Adijiang A, Goto S, Uramoto S, et al. Indoxyl sulphate promotes aortic calcification with expression of osteoblast-specific proteins in hypertensive rats. Nephrol Dial Transplant 2008; 23: 1892-1901
61. Chang YL, Hung SH, Ling W, et al. Association between ischemic stroke and iron-deficiency anemia: a population-based study. PLoS One 2013; 8: e82952
62. Abramson JL, Jurkovitz CT, Vaccarino V, et al. Chronic kidney disease, anemia, and incident stroke in a middle-Aged, community-based population: the ARIC Study. Kidney Int 2003; 64: 610-615
63. Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011; 377: 2181-2192
64. Ridker PM, MacFadyen J, Cressman M, et al. Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention-An Intervention Trial Evaluating Rosuvastatin) trial. J Am Coll Cardiol 2010; 55: 1266-1273
65. Zhang X, Xiang C, Zhou YH, et al. Effect of statins on cardiovascular events in patients with mild to moderate chronic kidney disease: a systematic review and meta-Analysis of randomized clinical trials. BMC Cardiovasc Disord 2014; 14: 19
66. Hou W, Lv J, Perkovic V, et al. Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta-Analysis. Eur Heart J 2013; 34: 1807-1817
67. Palmer SC, Navaneethan SD, Craig JC et al.HMGCoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev 2014; 5: CD007784
68. Massy ZA, de Zeeuw D. LDL cholesterol in CKD-To treat or not to treat? Kidney Int 2013; 84: 451-456
69. Perkovic V, Ninomiya T, Arima H, et al. Chronic kidney disease, cardiovascular events, and the effects of perindopril-based blood pressure lowering: data from the PROGRESS study. J Am Soc Nephrol 2007; 18: 2766-2772
70. Ninomiya T, Perkovic V, Gallagher M, et al. Lower blood pressure and risk of recurrent stroke in patients with chronic kidney disease: PROGRESS trial. Kidney Int 2008; 73: 963-970
71. Iseki K, Arima H, Kohagura K, et al. Effects of angiotensin receptor blockade (ARB) on mortality and cardiovascular outcomes in patients with longterm haemodialysis: a randomized controlled trial. Nephrol Dial Transplant 2013; 28: 1579-1589
72. Rahman M, Ford CE, Cutler JA, et al. Long-Term renal and cardiovascular outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants by baseline estimated GFR. Clin J Am Soc Nephrol 2012; 7: 989-1002
73. Hermida RC, Ayala DE, Mojon A, et al. Bedtime dosing of antihypertensive medications reduces cardiovascular risk in CKD. J Am Soc Nephrol 2011; 22: 2313-2321
74. Seliger SL, Zhang AD, Weir MRet al. Erythropoiesis-stimulating agents increase the risk of acute stroke in patients with chronic kidney disease. Kidney Int 2011; 80: 288-294
75. Vinhas J, Barreto C, Assuncao J, et al. Treatment of anaemia with erythropoiesis-stimulating agents in patients with chronic kidney disease does not lower mortality and may increase cardiovascular risk: a meta-Analysis. Nephron Clin Pract 2012; 121: c95-c101
76. Palmer SC, Navaneethan SD, Craig JC, et al. Meta-Analysis: erythropoiesisstimulating agents in patients with chronic kidney disease. Ann Intern Med 2010; 153: 23-33
77. Pfeffer MA, Burdmann EA, Chen CY, et al A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361: 2019-2032
78. Singh NP, Sahni V, Wadhwa A, et al. Effect of improvement in anemia on electroneurophysiological markers (P300) of cognitive dysfunction in chronic kidney disease. Hemodial Int 2006; 10: 267-273
79. Alexander M, Kewalramani R, Agodoa I, et al. Association of anemia correction with health related quality of life in patients not on dialysis. Curr Med Res Opin 2007; 23: 2997-3008
80. Al-Qahtani JM, Abdel-Wahab BA, Abd El-Aziz SM. Long-Term moderate dose exogenous erythropoietin treatment protects from intermittent hypoxia-induced spatial learning deficits and hippocampal oxidative stress in young rats. Neurochem Res 2014; 39: 161-171
81. Fujisaki K, Tsuruya K, Yamato M, et al. Cerebral oxidative stress induces spatial working memory dysfunction in uremic mice: neuroprotective effect of tempol. Nephrol Dial Transplant 2014; 29: 529-538
82. Jun M, Venkataraman V, Razavian M, et al. Antioxidants for chronic kidney disease. Cochrane Database Syst Rev 2012; 10: CD008176
83. Chow KM, Szeto CC, Kwan BC, et al. Effect of cinacalcet treatment on vascular arterial stiffness among peritoneal dialysis patients with secondary hyperparathyroidism. Nephrology (Carlton) 2014; 19: 339-344
84. Chertow GM, Block GA, Correa-Rotter R, et al. Effect of cinacalcet on cardiovasculardisease in patients undergoingdialysis.NEngl JMed2012; 367: 2482-2494
85. Parfrey PS, Drueke TB, Block GA, et al. The effects of cinacalcet in older and younger patients on hemodialysis: the evaluation of cinacalcet HCl therapy to lower cardiovascular events (EVOLVE) trial. Clin J Am Soc Nephrol 2015; 10: 791-799